The Possible Antidiabetic Effects of Ranolazine Versus Glimepiride In STZ-Induced Type 2 Diabetes In Male Wistar Rats

Document Type : Original Article

Author

Clinical pharmacology department- faculty of medicine - portsaid university

Abstract

Abstract
Background: Type 2 diabetes is a major illness that distresses millions of people. The crucial causes of type 2 diabetes are insulin resistance and decreased insulin secretion
Objectives: To evaluate the possible effects of ranolazine versus glimepiride on blood glucose levels, HbA1c, nitric oxide and oxidative stress markers in STZ-induced type 2 diabetes in male Wistar rats and their effect on the histopathological picture of the pancreas.
Materials and Methods: Forty male Wistar rats were divided into four groups.  The normal control group which received saline (1 mg/kg/day) for 5 weeks. The diabetic control group that received saline (1 mg/kg/day) for 5 weeks. The glimepiride-treated group that received glimepiride ((0.1 mg/kg/day)) once daily for 5 weeks and the ranolazine-treated group that received ranolazine (20 mg/kg) twice daily for 5 weeks. Body weight and fasting blood glucose levels were measured weekly for the 5 weeks, then blood samples were attained for several biochemical analysis: lipid profile, HbA1c, and AGEs. Then rats were sacrificed and the pancreatic tissues were attained for oxidative stress markers assessment, and for histopathological examination using hematoxylin and eosin stain.
Results: Ranolazine improved diabetes by reducing fasting blood glucose level, HbA1c, and AGEs. Furthermore, it improved the oxidative stress markers, and the histopathological picture of the pancreas.
Conclusion: Ranolazine has the potential to become an innovative agent for treating type 2 diabetes patients.

Keywords

Main Subjects

Files

Share

How to cite

Statistics